Business Context and Reporting Period
Aardvark Therapeutics, Inc. (AARD) filed a Form 8-K on March 23, 2026, to report financial results for the quarter and full year ended December 31, 2025. The filing also includes pipeline and business updates detailed in an accompanying press release (Exhibit 99.1).
Key Financial Metrics
The provided filing text serves as a cover document and does not contain specific numerical data. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this excerpt. Investors must refer to the full text of the press release (Exhibit 99.1) for these figures.
Material Changes
The filing text does not provide specific details regarding material changes versus prior periods. It only indicates that such results were reported in the referenced press release.
Guidance, Outlook, and Risks
Management provided pipeline and business updates in the press release, but the specific content of the outlook, guidance, risks, or contingencies is not included in the Form 8-K text itself. The filing explicitly states that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual financial figures for Q4 and FY 2025.
- Verify specific pipeline milestones and business updates mentioned in the press release.
- Confirm the company's status as an emerging growth company and any election regarding extended transition periods for accounting standards.
- Note that the financial data in the press release is not incorporated by reference into this specific 8-K filing for liability purposes under Section 18.